Mankind Pharma (BOM:543904) EV-to-EBIT : 47.24 (As of May. 13, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mankind Pharma's Enterprise Value is ₹874,852 Mil. Mankind Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹18,519 Mil. Therefore, Mankind Pharma's EV-to-EBIT for today is 47.24.

The historical rank and industry rank for Mankind Pharma's EV-to-EBIT or its related term are showing as below:

BOM:543904' s EV-to-EBIT Range Over the Past 10 Years
Min: 30.89 Med: 36.46 Max: 47.24
Current: 47.24

During the past 3 years, the highest EV-to-EBIT of Mankind Pharma was 47.24. The lowest was 30.89. And the median was 36.46.

BOM:543904's EV-to-EBIT is ranked worse than
85.31% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.91 vs BOM:543904: 47.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Mankind Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was ₹794,386 Mil. Mankind Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹18,519 Mil. Mankind Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.33%.

Mankind Pharma EV-to-EBIT Historical Data

The historical data trend for Mankind Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma EV-to-EBIT Chart

Mankind Pharma Annual Data

Trend

Mar20

Mar21

Mar22

EV-to-EBIT

Mankind Pharma Quarterly Data
	Mar20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial					-	-	43.65	41.78	42.90

Competitive Comparison of Mankind Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mankind Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's EV-to-EBIT falls into.

Mankind Pharma EV-to-EBIT Calculation

Mankind Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	874852.331	/	18519.312
	=	47.24

Mankind Pharma's current Enterprise Value is ₹874,852 Mil.
Mankind Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹18,519 Mil.

Mankind Pharma (BOM:543904) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Mankind Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	18519.312	/	794386.0334
	=	2.33 %

Mankind Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was ₹794,386 Mil.
Mankind Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹18,519 Mil.

Mankind Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mankind Pharma (BOM:543904) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » EV-to-EBIT

Traded in Other Exchanges

MANKIND:India

Address

262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020

Website

https://www.mankindpharma.com

Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines